The benefit of radiation therapy was independent of the nodal status Following lumpectomy alone most recurrences occurred within the first 5 years (73.2%) but in the irradiated group most occurred after the first 5 years (59.5%)
The DFS for the whole group was 36.8% There were no differences in DFS, DDFS and OS among the 3 treatment arms (p=0. 26, p=0.34, p=0.57, respectively) There was a nearly significant increase in DFS for the lumpectomy plus irradiation group, as compared with the lumpectomy alone group (OR, 0.87; P=0.07)
The most frequent first events were distant recurrences (in 24.5%) Lumpectomy followed by irradiation, as compared with lumpectomy alone, was associated with a marginally significant decrease in deaths due to breast cancer (OR, 0.82; P=0.04) partially offset by an increase in deaths from other causes (OR, 1.23; P=0.21) Author's Conclusions After 20 years of follow-up, no significant difference in overall survival among women who underwent mastectomy and those who underwent lumpectomy with or without postoperative breast irradiation was found. The risk of death due to breast cancer was slightly reduced after lumpectomy and irradiation as compared with lumpectomy alone. The incidence of a recurrence in the ipsilateral breast is significantly reduced by lumpectomy and breast irradiation, as compared with lumpectomy alone. A substantial proportion of events occur after five years of follow-up.
No increase in the risk of cancer in the contralateral breast was observed with the use of postoperative breast irradiation.
Discussion
Breast-conserving surgery plus whole breast radiotherapy (BCT) yields equivalent long-term overall survival to mastectomy and high rates of local control even for stage I and II breast carcinomas with poor prognostic features
The study confirm the findings of the meta-analyses reported by the Early Breast Cancer Trialists' Collaborative GrouP</li> Most women with early stage breast cancer are candidates for BCT provided that the margins of lumpectomy specimens are free of tumor, and therefore, every woman should be informed about BCT as an alternative and of the suitability of the procedure in her particular case Continued follow-up long after BCT is indicated Local failures that occur many years after BCT often represent new primary tumors Systemic therapy is now frequently administered after lumpectomy, regardless of nodal status, to reduce the risk of distant metastases as well as reduce the rate of ipsilateral breast tumor recurrence The incidence of local recurrence among women with negative nodes who receive modern systemic therapy in addition to radiation therapy is about 5% at 10 years Although controversy exists on whether lumpectomy or quadrantectomy is preferable, it would be inappropriate to choose between them on the basis of a comparison of this NSABP trial and the study by Veronesi et al. because of significant differences in the patient populations in the two trials OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider. 
